Eli Lilly and Company (LLY) stock prices updated...
 

Eli Lilly and Company stock price

Eli Lilly and Company latest news:


  • 09/14/2017 09:35:18

    CORRECTED-Lilly/Incyte pill beats placebo in mid-stage eczema trial

    Sept 14 (Reuters) - Eli Lilly and Co and Incyte Corp on Thursday said a mid-stage trial of their oral drug baricitinib showed that at the highest dose it worked better than placebo for people with moderate-to-severe atopic dermatitis.

  • 09/07/2017 10:35:44

    Lilly to lay off 8 percent of employees in bid to cut costs

    (Reuters) - Eli Lilly and Co said on Thursday it would lay off about 8 percent of its employees as the drugmaker, which has suffered setbacks over the past year in the development of two potential blockbuster drugs, works to cut costs.

  • 09/07/2017 10:32:00

    UPDATE 3-Lilly to lay off 8 pct of employees in bid to cut costs

    Sept 7 (Reuters) - Eli Lilly and Co said on Thursday it would lay off about 8 percent of its employees as the drugmaker, which has suffered setbacks over the past year in the development of two potential blockbuster drugs, works to cut costs.

  • 09/07/2017 09:22:55

    Lilly to cut 8 percent of jobs in bid to cut costs

    (Reuters) - Eli Lilly and Co said on Thursday it would lay off about 8 percent of its employees as the drugmaker, which has suffered setbacks over the past year in the development of two potential blockbuster drugs, works to cut costs.

  • 09/07/2017 07:31:22

    Eli Lilly to cut 3,500 jobs after part of cost cutting plan

    Eli Lilly & Co. said it will cut about 3,500 jobs, or about 8.3% of its global workforce, as part of a streamlining plan aimed at cutting costs by $500 million a year. The drug giant expects most of the job cuts to come in the U.S. from a voluntary early retirement program, which it expects to be mostly completed by the end of the year. Other workforce reductions are expected to come from streamlining moves, including site closures. Lilly expects to record charges of $1.2 billion, or 80 cents a share, in the third and fourth quarters of 2017. The company plans to use the cost savings to improve its cost structure and reinvest in its business. "The actions we are announcing today will result in a leaner, more nimble global organization and will accelerate progress towards our long-term goals of growing revenue, expanding operating margins and sustaining the flow of life-changing medicines from our pipeline," said Chief Executive David Ricks. The stock, which slipped less than 0.1%, has gained 9.5% year to date through Wednesday, while the SPDR S&P Pharmaceuticals ETF has rallied 8.9% and the S&P 500 has tacked on 10%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/30/2017 13:23:46

    Incyte shares surge 10% on news that it and Eli Lilly will re-file for arthritis drug approval

    Incyte Corp. shares soared 10.1% in extremely heavy Wednesday trade after news that it and Eli Lilly & Co. plan to reapply for approval of rheumatoid arthritis drug baricitinib by the end of January 2018, with a decision expected mid-year. Eli Lilly shares rose 2.5% in heavy Wednesday trade. The Food and Drug Administration previously failed to approve the drug, asking for more clinical data on dosage and to clarify safety concerns. The two companies said they had discussed the matter with the FDA in late August and that the resubmission package would include new safety and efficacy data. Baricitinib is intended for moderate-to-severe rheumatoid arthritis, can be taken once a day and is expected to generate more than $2 billion in sales a year. Incyte shares have surged 5.7% over the last three months and Eli Lilly shares have surged 2.8%, compared with a 1.9% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 07/26/2017 07:10:09

    Top Analyst Upgrades and Downgrades: BP, Chipotle, Citigroup, Electronic Arts, Eli Lilly, McDonald’s, Texas Instruments, US Steel and More


  • 07/25/2017 09:28:35

    UPDATE 3-Lilly signals long delay for arthritis drug, shares fall

    July 25 (Reuters) - Eli Lilly and Co on Tuesday outlined a likely multi-year delay for its experimental rheumatoid arthritis drug with blockbuster sales potential, and disappointed investors sent its shares down nearly 4 percent.

  • 07/12/2017 08:29:48

    Eli Lilly settlement will result in Cialis patent expiring as early as 2018, rather than 2020

    Eli Lilly & Co. said on Wednesday that as part of a settlement with generic companies over its Cialis patent, the exclusive patent is now expected to end on September 27, 2018 at the earliest, roughly a year-and-a-half earlier than the patent was going to expire. The settlement won't affect 2017 financial guidance or mid-term expectations through the rest of the decade, the company said. The dispute centered around a patent on the unit dose of the drug. Eli Lilly defended the disputed patent as "valid" but said that "this is a royalty-bearing license agreement that provides us with more certainty regarding our U.S. exclusivity," according to Michael Harrington, the company's senior vice president and general counsel. Cialis treats erectile dysfunction, but the drug -- tadalfil -- is also sold under the name Adcirca for pulmonary arterial hypertension. Adcirca's patent is still expected to expire on November 21, 2017 or, if the Food and Drug Administration grants the company pediatric exclusivity, on May 21, 2018, Eli Lilly said. Eli Lilly shares rose 1.8% to $83.80 in morning trade. Shares have dropped 2.9% over the last three months, compared with a 4.2% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Ellie MaeELLI | Ellington Financial LLCEFC | Ellington Residential Mortgage REITEARN | Embotelladora Andina S.A.AKO.A | Embotelladora Andina S.A.AKO.B | Embraer-Empresa Brasileira de AeronauticaERJ | EMC CorporationEMC | EMCOR GroupEME | Emerge Energy Services LPEMES | Emergent BiosolutionsEBS |